Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the field of ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity, ...

"Palatin concludes Phase II trial of combination therapy for obesity" was originally created and published by Clinical Trials ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

Sen. Dick Durbin (D-Ill.) and Sen. Dr. Roger Marshall (R-Kan.) sent a letter to Food and Drug Administration acting ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...

Online sellers of knockoff GLP-1 drugs have seized on shortages as an opportunity to advertise a more steady, lower-cost supply of the products compared to branded versions. One such company, Hims & ...

StockNews.com started coverage on shares of vTv Therapeutics (NASDAQ:VTVT – Free Report) in a research report report published on Wednesday. The brokerage issued a sell rating on the biotechnology ...

Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...